Introduction
Material and Methods
Patients and Tumors
Gender (boys/girls) | 13/8 |
Total number of specimens examined | 36 |
Specimens obtained biopsy/surgery | 11/25* |
Specimens before/after chemotherapy | 21/15* |
Age at diagnosis (range) | 1 week–10 years and 9 months |
Age at diagnosis (median in months) | 21 |
INSS stage 1/2/3/4/4S | 2/7/2/9/1 |
Site of tumor: retroperitoneal/thoracic/neck/pelvic | 10/7/2/2 |
Survivors follow-up (range in years) | 9–24 |
Survivors follow-up (median in years) | 19 |
MYCN amplification | 6 |
Deaths | 8 |
Immunohistochemistry
NB Specimens
Control Tissue
Semiquantitative Calculation of Immunoreactive Cells
Results
Histopathology of Neuroblastoma Tissue Specimens
Expression of General NE Markers
Pat. no. | Age at diagnosis | Stage | Localization | Surgery/biopsy | Outcome | CgA | Syn | SV2 | VMAT1 | VMAT2 |
---|---|---|---|---|---|---|---|---|---|---|
Before chemotherapy | ||||||||||
1 | 2 m | III | Thoracic | Surgery | Alive | ++++ | ++ | ++++ | 0 | +++ |
2 | 11 m | II | Thoracic | Surgery | Alive | +++++ | +++++ | +++++ | ++ | +++++ |
3 | 1 m | II | Thoracic | Surgery | Alive | +++++ | +++++ | +++++ | ++++ | ++++ |
4 | 2 y and 6 m | II | Thoracic | Surgery | Alive | +++++ | +++++ | +++++ | ++ | ++++ |
5 | 8 mo | I | Thoracic | Surgery | Alive | ++++ | + | ++++ | + | ++++ |
6 | 1 y and 2 m | II | Neck/thoracic | Surgery | Alive | +++++ | ++++ | +++++ | + | +++++ |
7 | 2 m | I | Retroperitoneal | Surgery | Alive | +++++ | ++ | +++++ | ++++ | +++++ |
9 | 2 y and 1 m | II | Thoracic | Surgery | Alive | +++++ | +++++ | +++++ | ++++ | +++++ |
10 | 1 w | IVS | Retroperitoneal | Surgery | Alive | +++++ | 0 | +++++ | +++ | +++++ |
11 | 7 y 8 m | IV | Thoracic | Surgery | Alive | +++++ | ++++ | +++++ | 0 | ++ |
13 | 4 y | IV | Retroperitoneal | Biopsy | Dead | Missing | Missing | +++++ | +++ | ++++ |
15 | 7 m | III | Pelvic | Biopsy | Alive | +++++ | +++++ | +++++ | Missing | Missing |
18 | 10 y and 9 m | IV | Retroperitoneal | Biopsy | Dead | ++++ | ++++ | ++++ | 0 | +++++ |
20 | 3 y and 1 m | IV | Retroperitoneal | Biopsy | Dead | ++++ | ++ | ++++ | 0 | 0 |
21 | 1 y | IV | Retroperitoneal | Biopsy | Dead | ++ | missing | +++++ | 0 | ++++ |
After chemotherapy | ||||||||||
8 | 4 y and 1 m | IV | Retroperitoneal | Surgery | Dead | +++++ | +++++ | +++++ | 0 | 0 |
12 | 3 y and 1 m | IV | Retroperitoneal | Surgery | Dead | Missing | Missing | Missing | 0 | + |
13 | 4 y | IV | Retroperitoneal | Surgery | Dead | Missing | +++++ | +++++ | +++++ | +++++ |
14 | 4 y and 8 m | III | Retroperitoneal | Surgery | Dead | Missing | ++++ | +++++ | 0 | +++ |
16 | 1 y | IV | Retroperitoneal | Surgery | Dead | +++++ | ++++ | +++++ | 0 | 0 |
17 | 7 y and 5 m | IV | Neck/thoracic | Surgery | Alive | +++++ | +++++ | +++++ | ++++ | +++++ |
19 | 1 y and 10 m | II | Pelvic | Surgery | Alive | +++ | + | ++ | Missing | Missing |
20 | 3 y and 1 m | IV | Retroperitoneal | Surgery | Dead | +++++ | ++ | +++++ | 0 | ++ |
Before Chemotherapy
After Chemotherapy
Monoamine Transporters VMAT1 and 2
Before Chemotherapy
After Chemotherapy
Comparison of the Immunoreactivity Between All Studied Neuroendocrine Markers
≥ 90% +++++ | 70–< 90% ++++ | 50–< 70% +++ | 10–< 50% ++ | < 10% + | 0% 0 | |
---|---|---|---|---|---|---|
Before chemotherapy n = 12 | ||||||
CgA | 8 | 4 | 0 | 0 | 0 | 0 |
syn | 4 | 3 | 0 | 3 | 1 | 1 |
SV2 | 8 | 4 | 0 | 0 | 0 | 0 |
VMAT1 | 0 | 3 | 1 | 2 | 2 | 4 |
VMAT2 | 6 | 4 | 1 | 1 | 0 | 0 |
After chemotherapy n = 4 | ||||||
CgA | 4 | 0 | 0 | 0 | 0 | 0 |
SYN | 2 | 1 | 0 | 1 | 0 | 0 |
SV2 | 4 | 0 | 0 | 0 | 0 | 0 |
VMAT1 | 0 | 1 | 0 | 0 | 0 | 3 |
VMAT2 | 1 | 0 | 0 | 1 | 0 | 2 |